The compliance of patients with medication prescribed for them is a challenge. It seems that one-third of patients comply adequately, one-third more-or-less, and one-third are non-compliant, so that compliance rates hover around 50%. This can be improved upon, but not by treating failure to comply as a deplorably aberrant behaviour. First we need to know more about compliance and non-compliance, and that means standardising methods of study and measuring, by questioning the patient, counting tablets, or looking at drug metabolites or markers in faeces, blood or urine. Doctors' prejudices and patients' perceptions alike have to be taken into account since strategies for improvement must include both educating the prescriber and counselling the patient.

Fibromyalgia syndrome is generally taken to denote a clinical state of widespread musculoskeletal pain, stiffness, and fatigue but its pathophysiology, physical and psychological, is unknown, and the nature of the diagnostically mandatory "tender points" remains obscure. Diagnostic criteria convey no pathophysiological insight and they have been "validated" via a circular argument in which the evidence on which the construct is based is taken as proof of its veracity. The concept of fibromyalgia syndrome is valid only in the sense that it includes all possibilities. An alternative approach to this very real clinical presentation is via secondary hyperalgesia.

According to Darwin's theory of sexual selection some features that differentiate the two sexes evolve by a process of "male competition" and "female choice". The sex difference in age of onset of psychotic illness in man may relate to a sexual dimorphism in cerebral organisation (the male brain being more lateralised or asymmetrical than the female brain), a difference consistent with a role for sexual selection in the evolution of the human brain. Differing criteria (reflected in a cross-culturally stable difference in mean age at marriage) in males and females for selecting personality characteristics in a mate may generate diversity in the balance of growth between the hemispheres, and this could maintain the high and relatively constant rates of psychosis in human populations.

Management of stroke patients in specialist stroke units hastens recovery but is not believed to influence mortality. We did a statistical overview of randomised controlled trials reported between 1962 and 1993 in which the management of stroke patients in a specialist unit was compared with that in general wards. We identified 10 trials, 8 of which used a strict randomisation procedure. 1586 stroke patients were included; 766 were allocated to a stroke unit and 820 to general wards. The odds ratio (stroke unit vs general wards) for mortality within the first 4 months (median follow-up 3 months) after the stroke was 0.72 (95% CI 0.56-0.92), consistent with a reduction in mortality of 28% (2p < 0.01). This reduction persisted (odds ratio 0.79, 95% CI 0.63-0.99, 2p < 0.05) when calculated for mortality during the first 12 months. The findings were not significantly altered if the analysis was limited to studies that used a formal randomisation procedure. We conclude that management of stroke patients in a stroke unit is associated with a sustained reduction in mortality.

We did a meta-analysis of all published polychemotherapy vs supportive care clinical trials in patients with non-resectable non small cell lung cancer. 7 studies with more than 700 patients were selected. We used the number of deaths at 3, 6, 9, 12, and 18 months as the endpoints because we were unable to obtain all the individual data. Our analysis showed a reduction in mortality during the first 6 months with polychemotherapy. Although small, this increase in survival, together with an improved quality of life, suggests that polychemotherapy should be recommended for patients with non-resectable non small cell lung cancer.